A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/01/28/a-bull-market-is-here-2-stocks-to-buy-and-hold-for/?source=iedfolrf0000001
Jan 28, 2024 - These companies can perform well through this bull run and beyond.
0
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214
Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
0
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580
Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
0
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567
Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
0
Merck (MRK) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2247735/merck-mrk-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2247735
Mar 28, 2024 - Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.
0
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2248395/why-merck-mrk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2248395
Apr 01, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
0
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
0
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375
Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
0
Page 1>